Cargando…
Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy
Despite a history dating back to the 1800s, using Clostridium bacteria to treat cancer has not advanced beyond the observation that they can colonise and partially destroy solid tumours. Progress has been hampered by their inability to eradicate the viable portion of tumours, and an instinctive anxi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217651/ https://www.ncbi.nlm.nih.gov/pubmed/34168629 http://dx.doi.org/10.3389/fmicb.2021.669488 |
_version_ | 1783710636426919936 |
---|---|
author | Kubiak, Aleksandra M. Bailey, Tom S. Dubois, Ludwig J. Theys, Jan Lambin, Philippe |
author_facet | Kubiak, Aleksandra M. Bailey, Tom S. Dubois, Ludwig J. Theys, Jan Lambin, Philippe |
author_sort | Kubiak, Aleksandra M. |
collection | PubMed |
description | Despite a history dating back to the 1800s, using Clostridium bacteria to treat cancer has not advanced beyond the observation that they can colonise and partially destroy solid tumours. Progress has been hampered by their inability to eradicate the viable portion of tumours, and an instinctive anxiety around injecting patients with a bacterium whose close relatives cause tetanus and botulism. However, recent advances in techniques to genetically engineer Clostridium species gives cause to revisit this concept. This paper illustrates these developments through the attenuation of C. sporogenes to enhance its clinical safety, and through the expression and secretion of an immunotherapeutic. An 8.6 kb sequence, corresponding to a haemolysin operon, was deleted from the genome and replaced with a short non-coding sequence. The resultant phenotype of this strain, named C. sporogenes-NT, showed a reduction of haemolysis to levels similar to the probiotic strain, C. butyricum M588. Comparison to the parental strain showed no change in growth or sporulation. Following injection of tumour-bearing mice with purified spores of the attenuated strain, high levels of germination were detected in all tumours. Very low levels of spores and vegetative cells were detected in the spleen and lymph nodes. The new strain was transformed with four different murine IL-2-expressing plasmids, differentiated by promoter and signal peptide sequences. Biologically active mIL-2, recovered from the extracellular fraction of bacterial cultures, was shown to stimulate proliferation of T cells. With this investigation we propose a new, safer candidate for intratumoral delivery of cancer immunotherapeutics. |
format | Online Article Text |
id | pubmed-8217651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82176512021-06-23 Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy Kubiak, Aleksandra M. Bailey, Tom S. Dubois, Ludwig J. Theys, Jan Lambin, Philippe Front Microbiol Microbiology Despite a history dating back to the 1800s, using Clostridium bacteria to treat cancer has not advanced beyond the observation that they can colonise and partially destroy solid tumours. Progress has been hampered by their inability to eradicate the viable portion of tumours, and an instinctive anxiety around injecting patients with a bacterium whose close relatives cause tetanus and botulism. However, recent advances in techniques to genetically engineer Clostridium species gives cause to revisit this concept. This paper illustrates these developments through the attenuation of C. sporogenes to enhance its clinical safety, and through the expression and secretion of an immunotherapeutic. An 8.6 kb sequence, corresponding to a haemolysin operon, was deleted from the genome and replaced with a short non-coding sequence. The resultant phenotype of this strain, named C. sporogenes-NT, showed a reduction of haemolysis to levels similar to the probiotic strain, C. butyricum M588. Comparison to the parental strain showed no change in growth or sporulation. Following injection of tumour-bearing mice with purified spores of the attenuated strain, high levels of germination were detected in all tumours. Very low levels of spores and vegetative cells were detected in the spleen and lymph nodes. The new strain was transformed with four different murine IL-2-expressing plasmids, differentiated by promoter and signal peptide sequences. Biologically active mIL-2, recovered from the extracellular fraction of bacterial cultures, was shown to stimulate proliferation of T cells. With this investigation we propose a new, safer candidate for intratumoral delivery of cancer immunotherapeutics. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8217651/ /pubmed/34168629 http://dx.doi.org/10.3389/fmicb.2021.669488 Text en Copyright © 2021 Kubiak, Bailey, Dubois, Theys and Lambin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Kubiak, Aleksandra M. Bailey, Tom S. Dubois, Ludwig J. Theys, Jan Lambin, Philippe Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy |
title | Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy |
title_full | Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy |
title_fullStr | Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy |
title_full_unstemmed | Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy |
title_short | Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy |
title_sort | efficient secretion of murine il-2 from an attenuated strain of clostridium sporogenes, a novel delivery vehicle for cancer immunotherapy |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217651/ https://www.ncbi.nlm.nih.gov/pubmed/34168629 http://dx.doi.org/10.3389/fmicb.2021.669488 |
work_keys_str_mv | AT kubiakaleksandram efficientsecretionofmurineil2fromanattenuatedstrainofclostridiumsporogenesanoveldeliveryvehicleforcancerimmunotherapy AT baileytoms efficientsecretionofmurineil2fromanattenuatedstrainofclostridiumsporogenesanoveldeliveryvehicleforcancerimmunotherapy AT duboisludwigj efficientsecretionofmurineil2fromanattenuatedstrainofclostridiumsporogenesanoveldeliveryvehicleforcancerimmunotherapy AT theysjan efficientsecretionofmurineil2fromanattenuatedstrainofclostridiumsporogenesanoveldeliveryvehicleforcancerimmunotherapy AT lambinphilippe efficientsecretionofmurineil2fromanattenuatedstrainofclostridiumsporogenesanoveldeliveryvehicleforcancerimmunotherapy |